Assertio Q2 net product sales $28.8M, net loss $16.4M, cash rises to $98.2M

Assertio Holdings, Inc.

2025-Q2 EPS reported -$0.31 vs consensus -$1.16 ▲ beat (+73.3%)

GAAP net loss $16.4M ($0.17 per share) vs $3.7M loss ($0.04) in prior year Q2.
Adjusted EBITDA $5.6M, up from $3.1M; adjusted EPS $0.02 vs $0.01.
Rolvedon sales $16.1M (+$1M YoY); Sympazan $3.2M (+$0.5M); Indocin $3.0M (down from $6.9M due to generic competition).
Cash & investments $98.2M, up from $87.3M at Q1 2025; company narrows guidance.
SG&A $17.0M, down from $18.4M, includes $2.4M employee retention tax credit benefit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.